250 related articles for article (PubMed ID: 26161550)
1. The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas.
Ji H; Xuan Q; Nanding A; Zhang H; Zhang Q
PLoS One; 2015; 10(7):e0132824. PubMed ID: 26161550
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype.
Lee K; Jang MH; Chung YR; Lee Y; Kang E; Kim SW; Kim YJ; Kim JH; Kim IA; Park SY
Hum Pathol; 2017 Mar; 61():111-120. PubMed ID: 27989787
[TBL] [Abstract][Full Text] [Related]
3. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer.
Varga Z; Tubbs RR; Wang Z; Sun Y; Noske A; Kradolfer D; Bosshard G; Jochum W; Moch H; Öhlschlegel C
Breast Cancer Res Treat; 2012 Apr; 132(3):925-35. PubMed ID: 21698407
[TBL] [Abstract][Full Text] [Related]
4. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
[TBL] [Abstract][Full Text] [Related]
5. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
6. HER2 expression in breast cancer with nonamplified HER2 and gains of chromosome 17 centromere.
Panvichian R; Tantiwetrueangdet A; Wongwaisayawan S; Nampoon A; Lertsithichai P; Leelaudomlipi S
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):367-74. PubMed ID: 22417858
[TBL] [Abstract][Full Text] [Related]
7. Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry.
Davies V; Voutsadakis IA
Cancer Invest; 2020 Feb; 38(2):94-101. PubMed ID: 31977265
[No Abstract] [Full Text] [Related]
8. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.
Jiang H; Bai X; Zhao T; Zhang C; Zhang X
Oncol Rep; 2014 Nov; 32(5):1889-96. PubMed ID: 25119636
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes.
Schildhaus HU; Schroeder L; Merkelbach-Bruse S; Binot E; Büttner R; Kuhn W; Rudlowski C
Breast; 2013 Dec; 22(6):1066-71. PubMed ID: 24080492
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
Fountzilas G; Dafni U; Bobos M; Kotoula V; Batistatou A; Xanthakis I; Papadimitriou C; Kostopoulos I; Koletsa T; Tsolaki E; Televantou D; Timotheadou E; Koutras A; Klouvas G; Samantas E; Pisanidis N; Karanikiotis C; Sfakianaki I; Pavlidis N; Gogas H; Linardou H; Kalogeras KT; Pectasides D; Dimopoulos MA
BMC Cancer; 2013 Mar; 13():163. PubMed ID: 23537287
[TBL] [Abstract][Full Text] [Related]
11. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.
Sneige N; Hess KR; Multani AS; Gong Y; Ibrahim NK
Cancer; 2017 Apr; 123(7):1115-1123. PubMed ID: 27893937
[TBL] [Abstract][Full Text] [Related]
13. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
[TBL] [Abstract][Full Text] [Related]
14. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With
Hoda RS; Brogi E; Xu J; Ventura K; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
Arch Pathol Lab Med; 2020 May; 144(5):597-601. PubMed ID: 31647316
[TBL] [Abstract][Full Text] [Related]
15. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
Moelans CB; de Weger RA; van Diest PJ
Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation and indication of human epithelial growth factor receptor 2 status in breast carcinoma with amplified chromosome].
Zhang S; Wang Y; Guo ZM; Zhang H; Xu L; Liu YH; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Oct; 46(5):686-90. PubMed ID: 25331387
[TBL] [Abstract][Full Text] [Related]
17. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
[TBL] [Abstract][Full Text] [Related]
18. HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.
Stocker A; Hilbers ML; Gauthier C; Grogg J; Kullak-Ublick GA; Seifert B; Varga Z; Trojan A
PLoS One; 2016; 11(7):e0159176. PubMed ID: 27463363
[TBL] [Abstract][Full Text] [Related]
19. Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH Using a Standard HER2/CEP17 Dual Probe and an Alternative Chromosome 17 Control Probe.
Zare S; Lin L; Alghamdi AG; Daehne S; Roma AA; Hasteh F; Dell'Aquila M; Fadare O
Am J Surg Pathol; 2018 Sep; 42(9):1208-1215. PubMed ID: 29923906
[TBL] [Abstract][Full Text] [Related]
20. The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry-equivocal invasive breast cancer.
Katayama A; Starczynski J; Toss MS; Shaaban AM; Provenzano E; Quinn CM; Callagy G; Purdie CA; Millican-Slater R; Purnell D; Chagla L; Oyama T; Pinder SE; Chan S; Ellis I; Lee AHS; Rakha EA
Histopathology; 2022 Oct; 81(4):511-519. PubMed ID: 35879836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
